Loading…
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emp...
Saved in:
| Published in: | Frontiers in endocrinology (Lausanne) 2021-11, Vol.12, p.772865 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723 |
| container_end_page | |
| container_issue | |
| container_start_page | 772865 |
| container_title | Frontiers in endocrinology (Lausanne) |
| container_volume | 12 |
| creator | Xie, Lingli Zhang, Ziying Wang, Qian Chen, Yangwen Lu, Dexue Wu, Weihua |
| description | The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emphasized the implications of ACE2 on SARS-CoV-2 infection and COVID-19 pathogenesis. Besides, we updated on the two-way interactions between diabetes and COVID-19, as well as the treatment options for COVID-19 comorbid patients from the perspective of ACE2. The efficacies of various clinical chemotherapeutic options, including anti-diabetic drugs, renin-angiotensin-aldosterone system inhibitors, lipid-lowering drugs, anticoagulants, and glucocorticoids for COVID-19 positive diabetic patients were discussed. Moreover, we reviewed the significance of two different forms of ACE2 (mACE2 and sACE2) and gender on COVID-19 susceptibility and severity. This review summarizes COVID-19 pathophysiology and the best strategies for clinical management of diabetes patients with COVID-19. |
| doi_str_mv | 10.3389/fendo.2021.772865 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5d89f52f8dc4470b98867d37ff096a95</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5d89f52f8dc4470b98867d37ff096a95</doaj_id><sourcerecordid>34867819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723</originalsourceid><addsrcrecordid>eNpVkV9uEzEQxlcIRKvSA_CCfAA2-M-u1-YBKUoDRCoqQsCrNWuPk62yduTdpAqn4SycDCdpq9Yv9oz9_cYzX1G8ZXQihNIfPAYXJ5xyNmkarmT9ojhnUlYlF5q_fHI-Ky6H4ZbmVVGmtXpdnIlKyUYxfV5sZze_F1cl0wSCI1cdtDji8JFMySz2m4QrDEO3Q_IDdx3ekejJNCy7OB7SIb8JO0xjF5ZkHv7se_z3l78n37bjFtZk7j3acTiCv68g9WDjuMIEm_2b4pWH9YCX9_tF8evz_Ofsa3l982Uxm16XtpL1WErJlGcekOm6BsuAakERectAAvXW6Vbm2OU6ldVSSjg0xRTjTinXcHFRLE5cF-HWbFLXQ9qbCJ05JmJaGsjft2s0tVPa19wrZ6uqoa1WeURONN5TLUHXmfXpxNps2x6dxTAmWD-DPr8J3cos484oKbSSMgPYCWBTHIaE_lHLqDlYao6WmoOl5mRp1rx7WvRR8WCg-A-YCZ_J</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy</title><source>PubMed Central</source><creator>Xie, Lingli ; Zhang, Ziying ; Wang, Qian ; Chen, Yangwen ; Lu, Dexue ; Wu, Weihua</creator><creatorcontrib>Xie, Lingli ; Zhang, Ziying ; Wang, Qian ; Chen, Yangwen ; Lu, Dexue ; Wu, Weihua</creatorcontrib><description>The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emphasized the implications of ACE2 on SARS-CoV-2 infection and COVID-19 pathogenesis. Besides, we updated on the two-way interactions between diabetes and COVID-19, as well as the treatment options for COVID-19 comorbid patients from the perspective of ACE2. The efficacies of various clinical chemotherapeutic options, including anti-diabetic drugs, renin-angiotensin-aldosterone system inhibitors, lipid-lowering drugs, anticoagulants, and glucocorticoids for COVID-19 positive diabetic patients were discussed. Moreover, we reviewed the significance of two different forms of ACE2 (mACE2 and sACE2) and gender on COVID-19 susceptibility and severity. This review summarizes COVID-19 pathophysiology and the best strategies for clinical management of diabetes patients with COVID-19.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2021.772865</identifier><identifier>PMID: 34867819</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>ACE2 (angiotensin converting enzyme 2) ; Aged ; Angiotensin-Converting Enzyme 2 - blood ; Animals ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - drug therapy ; Comorbidity ; COVID - 19 ; COVID-19 - complications ; COVID-19 - drug therapy ; Diabetes Complications - drug therapy ; diabetes mellitus ; Diabetes Mellitus - drug therapy ; Endocrinology ; Female ; Humans ; Hyperglycemia - metabolism ; Hypertension ; Inflammation ; Insulin Resistance ; Insulin-Secreting Cells - metabolism ; Male ; Middle Aged ; Obesity - complications ; Obesity - drug therapy ; receptor ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - drug therapy ; Risk ; Risk Factors ; SARS- CoV-2 ; therapeutic management</subject><ispartof>Frontiers in endocrinology (Lausanne), 2021-11, Vol.12, p.772865</ispartof><rights>Copyright © 2021 Xie, Zhang, Wang, Chen, Lu and Wu.</rights><rights>Copyright © 2021 Xie, Zhang, Wang, Chen, Lu and Wu 2021 Xie, Zhang, Wang, Chen, Lu and Wu</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723</citedby><cites>FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639866/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639866/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34867819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xie, Lingli</creatorcontrib><creatorcontrib>Zhang, Ziying</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Chen, Yangwen</creatorcontrib><creatorcontrib>Lu, Dexue</creatorcontrib><creatorcontrib>Wu, Weihua</creatorcontrib><title>COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emphasized the implications of ACE2 on SARS-CoV-2 infection and COVID-19 pathogenesis. Besides, we updated on the two-way interactions between diabetes and COVID-19, as well as the treatment options for COVID-19 comorbid patients from the perspective of ACE2. The efficacies of various clinical chemotherapeutic options, including anti-diabetic drugs, renin-angiotensin-aldosterone system inhibitors, lipid-lowering drugs, anticoagulants, and glucocorticoids for COVID-19 positive diabetic patients were discussed. Moreover, we reviewed the significance of two different forms of ACE2 (mACE2 and sACE2) and gender on COVID-19 susceptibility and severity. This review summarizes COVID-19 pathophysiology and the best strategies for clinical management of diabetes patients with COVID-19.</description><subject>ACE2 (angiotensin converting enzyme 2)</subject><subject>Aged</subject><subject>Angiotensin-Converting Enzyme 2 - blood</subject><subject>Animals</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Comorbidity</subject><subject>COVID - 19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - drug therapy</subject><subject>Diabetes Complications - drug therapy</subject><subject>diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperglycemia - metabolism</subject><subject>Hypertension</subject><subject>Inflammation</subject><subject>Insulin Resistance</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>receptor</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>SARS- CoV-2</subject><subject>therapeutic management</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV9uEzEQxlcIRKvSA_CCfAA2-M-u1-YBKUoDRCoqQsCrNWuPk62yduTdpAqn4SycDCdpq9Yv9oz9_cYzX1G8ZXQihNIfPAYXJ5xyNmkarmT9ojhnUlYlF5q_fHI-Ky6H4ZbmVVGmtXpdnIlKyUYxfV5sZze_F1cl0wSCI1cdtDji8JFMySz2m4QrDEO3Q_IDdx3ekejJNCy7OB7SIb8JO0xjF5ZkHv7se_z3l78n37bjFtZk7j3acTiCv68g9WDjuMIEm_2b4pWH9YCX9_tF8evz_Ofsa3l982Uxm16XtpL1WErJlGcekOm6BsuAakERectAAvXW6Vbm2OU6ldVSSjg0xRTjTinXcHFRLE5cF-HWbFLXQ9qbCJ05JmJaGsjft2s0tVPa19wrZ6uqoa1WeURONN5TLUHXmfXpxNps2x6dxTAmWD-DPr8J3cos484oKbSSMgPYCWBTHIaE_lHLqDlYao6WmoOl5mRp1rx7WvRR8WCg-A-YCZ_J</recordid><startdate>20211119</startdate><enddate>20211119</enddate><creator>Xie, Lingli</creator><creator>Zhang, Ziying</creator><creator>Wang, Qian</creator><creator>Chen, Yangwen</creator><creator>Lu, Dexue</creator><creator>Wu, Weihua</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211119</creationdate><title>COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy</title><author>Xie, Lingli ; Zhang, Ziying ; Wang, Qian ; Chen, Yangwen ; Lu, Dexue ; Wu, Weihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACE2 (angiotensin converting enzyme 2)</topic><topic>Aged</topic><topic>Angiotensin-Converting Enzyme 2 - blood</topic><topic>Animals</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Comorbidity</topic><topic>COVID - 19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - drug therapy</topic><topic>Diabetes Complications - drug therapy</topic><topic>diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperglycemia - metabolism</topic><topic>Hypertension</topic><topic>Inflammation</topic><topic>Insulin Resistance</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>receptor</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>SARS- CoV-2</topic><topic>therapeutic management</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xie, Lingli</creatorcontrib><creatorcontrib>Zhang, Ziying</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Chen, Yangwen</creatorcontrib><creatorcontrib>Lu, Dexue</creatorcontrib><creatorcontrib>Wu, Weihua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xie, Lingli</au><au>Zhang, Ziying</au><au>Wang, Qian</au><au>Chen, Yangwen</au><au>Lu, Dexue</au><au>Wu, Weihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2021-11-19</date><risdate>2021</risdate><volume>12</volume><spage>772865</spage><pages>772865-</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>The potential relationship between diabetes and COVID-19 has been evaluated. However, new knowledge is rapidly emerging. In this study, we systematically reviewed the relationship between viral cell surface receptors (ACE2, AXL, CD147, DC-SIGN, L-SIGN and DPP4) and SARS-CoV-2 infection risk, and emphasized the implications of ACE2 on SARS-CoV-2 infection and COVID-19 pathogenesis. Besides, we updated on the two-way interactions between diabetes and COVID-19, as well as the treatment options for COVID-19 comorbid patients from the perspective of ACE2. The efficacies of various clinical chemotherapeutic options, including anti-diabetic drugs, renin-angiotensin-aldosterone system inhibitors, lipid-lowering drugs, anticoagulants, and glucocorticoids for COVID-19 positive diabetic patients were discussed. Moreover, we reviewed the significance of two different forms of ACE2 (mACE2 and sACE2) and gender on COVID-19 susceptibility and severity. This review summarizes COVID-19 pathophysiology and the best strategies for clinical management of diabetes patients with COVID-19.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34867819</pmid><doi>10.3389/fendo.2021.772865</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1664-2392 |
| ispartof | Frontiers in endocrinology (Lausanne), 2021-11, Vol.12, p.772865 |
| issn | 1664-2392 1664-2392 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_5d89f52f8dc4470b98867d37ff096a95 |
| source | PubMed Central |
| subjects | ACE2 (angiotensin converting enzyme 2) Aged Angiotensin-Converting Enzyme 2 - blood Animals Cardiovascular Diseases - complications Cardiovascular Diseases - drug therapy Comorbidity COVID - 19 COVID-19 - complications COVID-19 - drug therapy Diabetes Complications - drug therapy diabetes mellitus Diabetes Mellitus - drug therapy Endocrinology Female Humans Hyperglycemia - metabolism Hypertension Inflammation Insulin Resistance Insulin-Secreting Cells - metabolism Male Middle Aged Obesity - complications Obesity - drug therapy receptor Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Risk Risk Factors SARS- CoV-2 therapeutic management |
| title | COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A23%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20and%20Diabetes:%20A%20Comprehensive%20Review%20of%20Angiotensin%20Converting%20Enzyme%C2%A02,%20Mutual%20Effects%20and%20Pharmacotherapy&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Xie,%20Lingli&rft.date=2021-11-19&rft.volume=12&rft.spage=772865&rft.pages=772865-&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2021.772865&rft_dat=%3Cpubmed_doaj_%3E34867819%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-6618f1fae1955ac1a0930ee2b1a6a0fcd9b60eedfec4c9666a78191812d88d723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34867819&rfr_iscdi=true |